Treatment of idiopathic Inflammatory myopathies

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorBercovici, Einav
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentSzántó, Antónia
dc.contributor.opponentBenkő, Ilona
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Belgyógyászati Intézethu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.date.accessioned2014-06-27T13:27:37Z
dc.date.available2014-06-27T13:27:37Z
dc.date.created2014
dc.date.issued2014-06-27T13:27:37Z
dc.description.abstractIdiopathic inflammatory myopathies are a group of rare, disorders with the primary features of muscle weakness and inflammatory lesions identified in skeletal muscle specimens. The IIM subtypes are, polymyositis(PM), dermatomyositis (DM) and inclusion body myositis (IBM). The leading pathomechanism theory for DM, is an autoimmune disorder involving deposition of autoantibodies in the microvasculature, which leads to complement activation and subsequently to capillary necrosis and a mixed leukocytic infiltration . PM pathological findings are characterized by infiltration of CD8+ lymphocytes invading muscle fibers with degenerating and regenerating fibers. IBM is associated with changes identical to PM, but also demonstrates lined vacuoles and deposits of beta-amyloid and ubiquitin. DM and PM may occur in isolation or in connection with a connective tissue disease or cancer. The fundamental, of therapy is corticosteroids with the addition of other immunosuppressives in severe or refractory disease or patients with intolerable side effects. The future of IIM treatment includes developing drugs in the field of biology pharmacology. It is a challenging task duo to the fact that relatively little is known about the diseases, and only a few trails where published concerning the long period of follow up on a specific treatment for IIM . Biologics therapies might play a key role in the management of IIM and hopefully achieves better results than conventional therapy. So far, the most encouraging evidence originates from the anti-CD20 therapy with satisfactory results reported, but this option still requires further investigation.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent31hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/194935
dc.language.isoenhu_HU
dc.rights.accessno_restrictionhu_HU
dc.subjectmyopathieshu_HU
dc.subjectInflammatory myopathieshu_HU
dc.subject.dspaceDEENK Témalista::Orvostudományhu_HU
dc.titleTreatment of idiopathic Inflammatory myopathieshu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)